AIM: To determine the trends in oxytocin use at a population level within New South Wales and to assess the maternal and neonatal morbidities associated with the use of oxytocin. METHODS: Trends in oxytocin use were assessed for women in NSW who were nulliparas at term with a singleton, cephalic fetus between 1998 and 2008. Maternal and neonatal morbidities were assessed in 2007-2008 using linked hospital and birth data with regression analysis. Oxytocin was also assessed by indication for use being either induction or augmentation of labour. RESULTS: The overall use of oxytocin increased from 10,291 (36.5%) of births in 1998 to 14,440 (45.4%) of births in 2008 (P < 0.0001) with the increase entirely because of the increased use for induction of labour. The use of oxytocin was associated with an increase in regional analgesia (65 to 22%), instrumental delivery (21 to 18%) and caesarean section (29 to 14%) as compared to women who did not receive oxytocin in labour. Oxytocin was also associated with an increase in severe maternal adjusted odds ratios ((aOR) 1.48, 95% CI 1.30-1.68) and neonatal morbidity (aOR 1.29, 95% CI 1.17-1.41). This increase in morbidity was maintained when both augmentation and induction were assessed separately. CONCLUSION: Oxytocin has an important role in the management of labour. However, its use should be carefully monitored with standardised treatment regimes to minimise maternal and neonatal morbidity.
AIM: To determine the trends in oxytocin use at a population level within New South Wales and to assess the maternal and neonatal morbidities associated with the use of oxytocin. METHODS: Trends in oxytocin use were assessed for women in NSW who were nulliparas at term with a singleton, cephalic fetus between 1998 and 2008. Maternal and neonatal morbidities were assessed in 2007-2008 using linked hospital and birth data with regression analysis. Oxytocin was also assessed by indication for use being either induction or augmentation of labour. RESULTS: The overall use of oxytocin increased from 10,291 (36.5%) of births in 1998 to 14,440 (45.4%) of births in 2008 (P < 0.0001) with the increase entirely because of the increased use for induction of labour. The use of oxytocin was associated with an increase in regional analgesia (65 to 22%), instrumental delivery (21 to 18%) and caesarean section (29 to 14%) as compared to women who did not receive oxytocin in labour. Oxytocin was also associated with an increase in severe maternal adjusted odds ratios ((aOR) 1.48, 95% CI 1.30-1.68) and neonatal morbidity (aOR 1.29, 95% CI 1.17-1.41). This increase in morbidity was maintained when both augmentation and induction were assessed separately. CONCLUSION:Oxytocin has an important role in the management of labour. However, its use should be carefully monitored with standardised treatment regimes to minimise maternal and neonatal morbidity.
Authors: D Schlembach; M G Mörtl; T Girard; W Arzt; E Beinder; C Brezinka; K Chalubinski; D Fries; W Gogarten; B-J Hackelöer; H Helmer; W Henrich; I Hösli; P Husslein; F Kainer; U Lang; G Pfanner; W Rath; E Schleussner; H Steiner; D Surbek; R Zimmermann Journal: Anaesthesist Date: 2014-03 Impact factor: 1.041
Authors: Dietmar Schlembach; Hanns Helmer; Wolfgang Henrich; Christian von Heymann; Franz Kainer; Wolfgang Korte; Maritta Kühnert; Heiko Lier; Holger Maul; Werner Rath; Susanne Steppat; Daniel Surbek; Jürgen Wacker Journal: Geburtshilfe Frauenheilkd Date: 2018-04-26 Impact factor: 2.915
Authors: Lilian L Peters; Charlene Thornton; Ank de Jonge; Ali Khashan; Mark Tracy; Soo Downe; Esther I Feijen-de Jong; Hannah G Dahlen Journal: Birth Date: 2018-03-25 Impact factor: 3.689